^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Melanoma |
| Drug: | cinrebafusp alfa (PRS-343) (HER2 inhibitor, CD137 agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
525O - A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies
Published date:
09/20/2020
Excerpt:
...we report the results of a phase I trial in patients with HER2+ solid tumors….with GC/GEJ (n=25); BC (n=16); gynecological cancer (n=6); CRC (n=10); BTC (n=5); UC (n=2); melanoma, pancreatic and salivary duct cancer (n=1 each) were treated with PRS-343....PRS-343 is the first 4-1BB bispecific to demonstrate encouraging evidence of safety and clinical benefit with a correlative PD effect.
Trial ID:
